Supernus Pharmaceuticals, Inc.
Financials
Valuation Metrics
Supernus Pharmaceuticals, Inc.'s Market Cap is $2.43B. At end of 2025 it was $2.85B. Ranked #1841 of 3,118 in US market (top 59%), #670 of 1,474 on NASDAQ (top 45%), #114 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 43%) by Market Cap.
Investment Metrics(as of 2026-10-30)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.43B | US#1,841/3,118 Sec#114/265 |
| Revenue | $865M | US#1,962/3,118 Sec#59/265 |
| Net Income | $-44M | US—/3,118 Sec—/265 |
| Total Assets | $1.40B | US#2,276/3,118 Sec#70/265 |
| Net Assets | $1.06B | US#1,733/3,118 Sec#60/265 |
| Employees | 778 | US#2,087/3,118 Sec#65/265 |
| Value | ||
| P/B | 2.29x | US#1,484/3,118 Sec#75/265 |
| P/S | 2.81x | US#1,687/3,118 Sec#50/265 |
| EV/EBITDA | 35.65x | US—/3,118 Sec—/265 |
| FCF Yield | 3.57% | US#2,183/3,118 Sec#81/265 |
| Profitability | ||
| ROE | -4.13% | US#2,372/3,118 Sec#81/265 |
| ROA | -3.14% | US#2,605/3,118 Sec#96/265 |
| Op. Margin | -3.51% | US#2,541/3,118 Sec#96/265 |
| Revenue Growth | 26.93% | US#527/3,118 Sec#66/265 |
| Financial Health | ||
| Debt Ratio | 31.55% | US#436/3,118 Sec#125/265 |
| Total Debt | $36M | US#2,628/3,118 Sec#160/265 |
| FCF | $87M | US#2,169/3,118 Sec#78/265 |
| Cash | $176M | US#1,812/3,118 Sec#120/265 |
| Current Ratio | 2.49x | US#1,174/3,118 Sec#217/265 |
| Net Debt/EBITDA | -2.17x | US—/3,118 Sec—/265 |
| Performance | ||
| 1Y Return | -25.81% | US#2,524/3,118 Sec#200/265 |
| 1M Return | -2.60% | US#2,021/3,118 Sec#134/265 |
| From 52W High | -29.76% | US#1,930/3,118 Sec#121/265 |
| 1Y MDD | -33.54% | US#1,548/3,118 Sec#79/265 |
| Trading | ||
| Volume | 2,818,900 shares | US#1,052/3,118 Sec#94/265 |
| Trading Value | $118M | US#1,063/3,118 Sec#62/265 |
| Per Share | ||
| EPS | $-0.76 | US—/3,118 Sec—/265 |
| BPS | $18.32 | US#1,358/3,118 Sec#37/265 |
Company Info
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; and SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.